-
States that do not require HIV testing in prison might consider an opt-out testing option that has been shown in North Carolina to dramatically increase HIV testing among inmates.
-
Evidence continues to mount in favor of starting HIV-infected patients on antiretroviral therapy (ART) soon after diagnosis. And San Francisco public health doctors are leading the way to making early treatment standard practice with new guidelines that recommend the practice.
-
Tuberculosis is the world's leading cause of death from HIV infection in most parts of the world, but other than a TB vaccine given to infants, little has been done to prevent the spread of TB in this population.
-
The Centers for Disease Control and Prevention recently updated its guidance on antiretroviral Therapy (ART) and sexual transmission in a question and answer format posted on one its websites. Highlights of the Q&A include:
-
CD4+ t cells were obtained from HIV-negative donors and HIV-positive patients receiving HAART with suppressed viremia. Using a single-cycle replication system and an X4 pseudovirus used to infect cells, minocycline, at concentrations from 0-50 ug/mL, demonstrated a dose-dependent reduction in the percentage of infected cells.
-
The Heinz Family Philanthropies, Welvista and Abbott recently announced a solution that will help HIV patients waiting for access to antiretroviral medications.
-
Adaora Adimora, MD, MPH, professor of medicine in the division of infectious disease at the University of North Carolina School of Medicine in Chapel Hill, NC, recently discussed her research on the nuances of HIV risk behavior among women with AIDS Alert.
-
A quick test can detect HIV. If HIV is caught early, you have the ability to give hope and impact a pregnant woman and the lifelong health of her infant, reminds Yvonne Green, RN, CNM, MSN, director of the office of women's health at Centers for Disease Control and Prevention.
-
The Food and Drug Administration recently approved revisions to the package insert for Sustiva (efavirenz), a non-nucleoside reverse transcriptase inhibitor, for both capsules and tablets, to include updates to the sections described below:
-
